Corimmun
Key Facts
| Invested since | 2006 |
| Based in | Martinsried |
About the company
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.
Exit since June 2012.
Corimmun in the news
More startups from Life Sciences
OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.
to OMEICOS
Exit
Amedrix develops & produces three dimensional implants (gel and liquid) based on collagen. Focus: treatment of articular cartilage damage in human an horse and other promising application areas. CE-mark for …
to Amedrix
Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – …
to Umlaut.bio
Exit
Research, development and marketing of high-precision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs.
to Scopis
Optimization of atrial fibrillation therapy via precise, non-thermal pulsed field ablation
to Argá Medtech
Skinuvita is a digital care model for the home use of phototherapy for chronic skin conditions such as psoriasis and neurodermatitis. With the innovative telemedicine system, the prescribed dose is …
to Skinuvita
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
to faCellitate
Exit
c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …
to c-LEcta
Exit
Novel antibody drug conjugates to treat high need cancers
to Emergence Therapeutics
Exit
adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species. Antibody …
to adivo
NAVAN, Inc. (NAVAN) is an early-stage private biotechnology company developing a novel, proprietary NanoStraw platform to enable the next generation of cell and gene therapies. A non-viral physical delivery technology, …
to Navan
TRIM TX is developing best-in-class Gamma-Secretase-Stabilizers (GSS) for the prevention and treatment of Alzheimer Disease.
to TRIM TX